Different studies proved that the derivatization of nanoparticle systems with the CD44 native ligand (HA) is a valuable approach to selectively target cancer cells, thus enhancing the uptake of a loaded therapeutic agent [22,23,24]. The gene discussed is CD44; the disease is cancer.